152 related articles for article (PubMed ID: 25256052)
1. DNA synthesis inhibitors for the treatment of gastrointestinal cancer.
Yasui H; Tsurita G; Imai K
Expert Opin Pharmacother; 2014 Nov; 15(16):2361-72. PubMed ID: 25256052
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies.
Temmink OH; Emura T; de Bruin M; Fukushima M; Peters GJ
Cancer Sci; 2007 Jun; 98(6):779-89. PubMed ID: 17441963
[TBL] [Abstract][Full Text] [Related]
3. The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed.
Hernando-Cubero J; Matos-García I; Alonso-Orduña V; Capdevila J
J Gastrointest Cancer; 2017 Jun; 48(2):135-147. PubMed ID: 28397102
[TBL] [Abstract][Full Text] [Related]
4. TAS-102: a novel antimetabolite for the 21st century.
Uboha N; Hochster HS
Future Oncol; 2016 Jan; 12(2):153-63. PubMed ID: 26616466
[TBL] [Abstract][Full Text] [Related]
5. S-1 for the treatment of gastrointestinal cancer.
Satoh T; Sakata Y
Expert Opin Pharmacother; 2012 Sep; 13(13):1943-59. PubMed ID: 22860709
[TBL] [Abstract][Full Text] [Related]
6. Recent development of anti-cancer drugs for treatment of GI malignancies in Japan.
Taguchi T
Gan To Kagaku Ryoho; 2002 Feb; 29 Suppl 1():76-80. PubMed ID: 11890118
[No Abstract] [Full Text] [Related]
7. TAS-106: preclinical, clinical and beyond.
Abdelrahim M; Matsuda A; Naing A
Oncology; 2013; 85(6):356-63. PubMed ID: 24335431
[TBL] [Abstract][Full Text] [Related]
8. Rationale for the use of metronomic chemotherapy in gastrointestinal cancer.
Filippi R; Lombardi P; Depetris I; Fenocchio E; Quarà V; Chilà G; Aglietta M; Leone F
Expert Opin Pharmacother; 2018 Sep; 19(13):1451-1463. PubMed ID: 30161003
[TBL] [Abstract][Full Text] [Related]
9. Colorectal Cancer Chemotherapy: The Evolution of Treatment and New Approaches.
McQuade RM; Stojanovska V; Bornstein JC; Nurgali K
Curr Med Chem; 2017; 24(15):1537-1557. PubMed ID: 28079003
[TBL] [Abstract][Full Text] [Related]
10. Preclinical perspectives on the use of platinum compounds in cancer chemotherapy.
Farrell NP
Semin Oncol; 2004 Dec; 31(6 Suppl 14):1-9. PubMed ID: 15726528
[TBL] [Abstract][Full Text] [Related]
11. Liposomal Nanostructures for Drug Delivery in Gastrointestinal Cancers.
Das M; Huang L
J Pharmacol Exp Ther; 2019 Sep; 370(3):647-656. PubMed ID: 30541917
[TBL] [Abstract][Full Text] [Related]
12. Perspectives on new chemotherapeutic agents in the treatment of colorectal cancer.
Clark JW
Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-19-S18-24. PubMed ID: 9420017
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Nukatsuka M; Nakagawa F; Takechi T
Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
[TBL] [Abstract][Full Text] [Related]
14. Overcoming resistance to cisplatin by inhibition of glutathione S-transferases (GSTs) with ethacraplatin micelles in vitro and in vivo.
Li S; Li C; Jin S; Liu J; Xue X; Eltahan AS; Sun J; Tan J; Dong J; Liang XJ
Biomaterials; 2017 Nov; 144():119-129. PubMed ID: 28834763
[TBL] [Abstract][Full Text] [Related]
15. Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, and genitourinary tumors and myeloma.
Belani CP
Semin Oncol; 2004 Dec; 31(6 Suppl 14):25-33. PubMed ID: 15726531
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin: The first metal based anticancer drug.
Ghosh S
Bioorg Chem; 2019 Jul; 88():102925. PubMed ID: 31003078
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin-induced acute thrombocytopenia.
Erdem GU; Dogan M; Demirci NS; Zengin N
J Cancer Res Ther; 2016; 12(2):509-14. PubMed ID: 27461601
[TBL] [Abstract][Full Text] [Related]
18. [Chemotherapy of advanced colorectal cancers after failure of a treatment with fluoropyrimidine].
Misset JL
Rev Prat; 1997 Jun; 47(12 Spec No):S29-35. PubMed ID: 9248091
[TBL] [Abstract][Full Text] [Related]
19. Novel developments in the use of antimetabolites.
Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):358-74. PubMed ID: 24940694
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint inhibitors in gastrointestinal cancers: Expectations and reality.
Kourie HR; Tabchi S; Ghosn M
World J Gastroenterol; 2017 May; 23(17):3017-3021. PubMed ID: 28533658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
